Cargando…

Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

Clear cell renal cell carcinoma (CC-RCC) remains one of the most deadly forms of kidney cancer despite recent advancements in targeted therapeutics, including tyrosine kinase and immune checkpoint inhibitors. Unfortunately, these therapies have not been able to show better than a 16% complete respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelson, Luke J, Castro, Kyleen E, Xu, Binzhi, Li, Junyi, Dinh, Nguyen B, Thompson, Jordan M, Woytash, Jordan, Kipp, Kevin R, Razorenova, Olga V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037521/ https://www.ncbi.nlm.nih.gov/pubmed/35240916 http://dx.doi.org/10.1080/15384101.2022.2041783

Ejemplares similares

Rho-Associated Kinase 1 (ROCK1) inhibition is Synthetically Lethal with Von Hippel Lindau (VHL) Deficiency in Clear Cell Renal Cell Carcinoma (CC-RCC)
por: Thompson, Jordan M., et al.
Publicado: (2016)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer
por: Howard, David, et al.
Publicado: (2022)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
por: Riess, Christin, et al.
Publicado: (2020)

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
por: Gojo, Ivana, et al.
Publicado: (2013)

The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
por: Desai, Brijal M., et al.
Publicado: (2013)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2016)

Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
por: Saqub, Hera, et al.
Publicado: (2020)

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Buzzetti, Marta, et al.
Publicado: (2021)

Synthetic lethal mutations in the cyclin A interface of human cytomegalovirus
por: Weisbach, Henry, et al.
Publicado: (2017)

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia
por: Flynn, Joseph, et al.
Publicado: (2015)

Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
por: Hu, Junhui, et al.
Publicado: (2023)

Exploring synthetic lethal network for the precision treatment of clear cell renal cell carcinoma
por: Liu, Zhicheng, et al.
Publicado: (2022)

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
por: Li, Kailin, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Synthetic Lethality Partners in DNA Damage Response
por: Kciuk, Mateusz, et al.
Publicado: (2022)

Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors
por: Moore, Lee E., et al.
Publicado: (2011)

Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines
por: Wang, Xuechun, et al.
Publicado: (2022)

MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma
por: Bailey, Sean T., et al.
Publicado: (2017)

Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance
por: Razafinjatovo, Caroline, et al.
Publicado: (2016)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
por: Mita, Monica M, et al.
Publicado: (2017)

Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene
por: Wykoff, C C, et al.
Publicado: (2004)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

Cytosine 5-hydroxymethylation regulates VHL gene expression in renal clear cell carcinoma
por: Ma, En-Guang, et al.
Publicado: (2017)

Kidney in VHL disease: Early clear cell proliferation occurs in the distal tubular system
por: Al-Gharaibeh, Nayef S., et al.
Publicado: (2022)

Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer
por: Howard, David, et al.
Publicado: (2021)

Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma
por: Sourbier, Carole, et al.
Publicado: (2012)

Loss of vhl in the zebrafish pronephros recapitulates early stages of human clear cell renal cell carcinoma
por: Noonan, Haley R., et al.
Publicado: (2016)

VHL Dependent Expression of REDD1 and PDK3 Proteins in Clear-cell Renal Cell Carcinoma
por: Ilic, Bojana B, et al.
Publicado: (2018)

Identification and validation of the clinical roles of the VHL-related LncRNAs in clear cell renal cell carcinoma
por: Yang, Wuping, et al.
Publicado: (2021)

Development and validation of a VHL-associated immune prognostic signature for clear cell renal cell carcinoma
por: Zhang, Jin, et al.
Publicado: (2020)

VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma
por: Ganner, Athina, et al.
Publicado: (2021)

Bcl-x(L) inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas
por: Rello-Varona, Santi, et al.
Publicado: (2019)

Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma
por: TAYLOR, CLAIRE, et al.
Publicado: (2012)

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
por: Nemunaitis, John J, et al.
Publicado: (2013)

Deciphering von Hippel-Lindau (VHL/Vhl)-Associated Pancreatic Manifestations by Inactivating Vhl in Specific Pancreatic Cell Populations
por: Shen, H.-C. Jennifer, et al.
Publicado: (2009)

Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review
por: Kim, Hyeong Su, et al.
Publicado: (2018)

VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2
por: Gao, Yao-Hui, et al.
Publicado: (2017)

Combined Vhl, Trp53 and Rb1 mutation causes clear cell renal cell carcinoma in mice
por: Harlander, Sabine, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_trpdfqtpph1b27bp2j6ar5qk8d